Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab in advanced melanoma (Ipi4)
NCT02068196Phase 4Active, not recruiting
- Sponsor
- Oslo University Hospital
- Start
- Jan 2014
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 4, open-label trial of ipilimumab in Malignant Melanoma (MM), sponsored by Oslo University Hospital. Primary endpoint: Number of Patients with Serious and Non-Serious Adverse Reactions at 5 years. Started Jan 2014; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02068196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02068196.